Thursday, October 31, 2013
A Canadian team has published
preclinical proof of concept that activating a transporter called KCC2
represents a new mechanism for treating neuropathic pain.1 The group
expects that compounds against the ion transporter will be safer than marketed
neuropathic pain drugs because its effects are restricted to malfunctioning
B. SciBX 6(42); doi:10.1038/scibx.2013.1179
Published online Oct. 31, 2013
M. et al. Nat. Med.; published online Oct. 6, 2013; doi:10.1038/nm.3356
Contact: Yves De Koninck, Universite Laval, Quebec City, Quebec, Canada
R. Nat. Med. 16, 1258-1266 (2010)
J.A.M. et al. Nature 424, 938-942 (2003)
J.A.M. et al. Nature 438, 1017-1021 (2005)
AND INSTITUTIONS MENTIONED
Elan Corp plc. (NYSE:ELN), Dublin, Ireland
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Hospital Center of Quebec Research Center, Quebec City, Quebec, Canada
Universite Laval, Quebec City, Quebec, Canada
Naurex Inc., Evanston, Ill.
NeurogesX Inc. (OTCBB:NGSX), San Mateo, Calif.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel
California, San Francisco, Calif.
Pittsburgh, Pittsburgh, Pa.